Early stage ovarian cancers: angiogenesis inhibition and clear cell cancers.

, , International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute. ,vol. 95, pp. 105- 112 ,(2003) , 10.1093/JNCI/95.2.105

Robert S. Mannel, Mark F. Brady, Elise C. Kohn, Parviz Hanjani, Masamichi Hiura, Roger Lee, Koen DeGeest, David E. Cohn, Bradley J. Monk, Helen Michael, A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study Gynecologic Oncology. ,vol. 122, pp. 89- 94 ,(2011) , 10.1016/J.YGYNO.2011.03.013

Noelle Gillette Cloven, Ainura Kyshtoobayeva, Robert A Burger, Ru Yu, John P Fruehauf, In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecologic Oncology. ,vol. 92, pp. 160- 166 ,(2004) , 10.1016/J.YGYNO.2003.09.030

Daniel J. Sargent, Chemotherapy: Failure of bevacizumab in early-stage colon cancer. Nature Reviews Clinical Oncology. ,vol. 8, pp. 10- 11 ,(2011) , 10.1038/NRCLINONC.2010.205

Robert C. Young, Leslie A. Walton, Susan S. Ellenberg, Howard D. Homesley, George D. Wilbanks, David G. Decker, Alexander Miller, Robert Park, Francis Major, Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. The New England Journal of Medicine. ,vol. 322, pp. 1021- 1027 ,(1990) , 10.1056/NEJM199004123221501

Maurie Markman, P.Y. Liu, Sharon Wilczynski, Bradley Monk, Larry J. Copeland, Ronald D. Alvarez, Caroline Jiang, David Alberts, Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial Journal of Clinical Oncology. ,vol. 21, pp. 2460- 2465 ,(2003) , 10.1200/JCO.2003.07.013

J. B. Trimbos, I. Vergote, G. Bolis, J. B. Vermorken, C. Mangioni, C. Madronal, M. Franchi, S. Tateo, G. Zanetta, G. Scarfone, L. Giurgea, P. Timmers, C. Coens, S. Pecorelli, Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial Journal of the National Cancer Institute. ,vol. 95, pp. 113- 125 ,(2003) , 10.1093/JNCI/95.2.113

M.A. Bookman, The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer Annals of Oncology. ,vol. 21, ,(2010) , 10.1093/ANNONC/MDQ368

DANIEL W. CRAMER, SUSAN S. DEVESA, WILLIAM R. WELCH, TRENDS IN THE INCIDENCE OF ENDOMETRIOID AND CLEAR CELL CANCERS OF THE OVARY IN THE UNITED STATES American Journal of Epidemiology. ,vol. 114, pp. 201- 208 ,(1981) , 10.1093/OXFORDJOURNALS.AJE.A113183